Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 64 entries
Sorted by: Best Match Show Resources per page
Vaccines Through Centuries: Major Cornerstones of Global Health.

Frontiers in public health

Hajj Hussein I, Chams N, Chams S, El Sayegh S, Badran R, Raad M, Gerges-Geagea A, Leone A, Jurjus A.
PMID: 26636066
Front Public Health. 2015 Nov 26;3:269. doi: 10.3389/fpubh.2015.00269. eCollection 2015.

Multiple cornerstones have shaped the history of vaccines, which may contain live-attenuated viruses, inactivated organisms/viruses, inactivated toxins, or merely segments of the pathogen that could elicit an immune response. The story began with Hippocrates 400 B.C. with his description...

Cite
Hajj Hussein I, Chams N, Chams S, et al. Vaccines Through Centuries: Major Cornerstones of Global Health. Front Public Health. 2015;3:269doi: 10.3389/fpubh.2015.00269.
Hajj Hussein, I., Chams, N., Chams, S., El Sayegh, S., Badran, R., Raad, M., Gerges-Geagea, A., Leone, A., & Jurjus, A. (2015). Vaccines Through Centuries: Major Cornerstones of Global Health. Frontiers in public health, 3269. https://doi.org/10.3389/fpubh.2015.00269
Hajj Hussein, Inaya, et al. "Vaccines Through Centuries: Major Cornerstones of Global Health." Frontiers in public health vol. 3 (2015): 269. doi: https://doi.org/10.3389/fpubh.2015.00269
Hajj Hussein I, Chams N, Chams S, El Sayegh S, Badran R, Raad M, Gerges-Geagea A, Leone A, Jurjus A. Vaccines Through Centuries: Major Cornerstones of Global Health. Front Public Health. 2015 Nov 26;3:269. doi: 10.3389/fpubh.2015.00269. eCollection 2015. PMID: 26636066; PMCID: PMC4659912.
Copy Download .nbib Format: NLM
Production and Use of Smallpox Vaccine Virus Cultivated in the Chorio-Allantoic Membrane of Chick Embryos.

American journal of public health and the nation's health

Buddingh GJ.
PMID: 18014733
Am J Public Health Nations Health. 1937 Nov;27(11):1135-40. doi: 10.2105/ajph.27.11.1135.

No abstract available.

Cite
Buddingh GJ. Production and Use of Smallpox Vaccine Virus Cultivated in the Chorio-Allantoic Membrane of Chick Embryos. Am J Public Health Nations Health. 1937;27(11):1135-40doi: 10.2105/ajph.27.11.1135.
Buddingh, G. J. (1937). Production and Use of Smallpox Vaccine Virus Cultivated in the Chorio-Allantoic Membrane of Chick Embryos. American journal of public health and the nation's health, 27(11), 1135-40. https://doi.org/10.2105/ajph.27.11.1135
Buddingh, G J. "Production and Use of Smallpox Vaccine Virus Cultivated in the Chorio-Allantoic Membrane of Chick Embryos." American journal of public health and the nation's health vol. 27,11 (1937): 1135-40. doi: https://doi.org/10.2105/ajph.27.11.1135
Buddingh GJ. Production and Use of Smallpox Vaccine Virus Cultivated in the Chorio-Allantoic Membrane of Chick Embryos. Am J Public Health Nations Health. 1937 Nov;27(11):1135-40. doi: 10.2105/ajph.27.11.1135. PMID: 18014733; PMCID: PMC1563315.
Copy Download .nbib Format: NLM
Complement-bound human antibodies to vaccinia virus B5 antigen protect mice from virus challenge.

Expert review of vaccines

Paran N, Lustig S.
PMID: 20218853
Expert Rev Vaccines. 2010 Mar;9(3):255-9. doi: 10.1586/erv.10.5.

The mechanism of protection afforded by vaccinia virus (VACV) - the smallpox vaccine - is a key issue for the development of modern vaccines and countermeasures. Antibodies to VACV antigens of the extracellular virion (EV) form play a central...

Cite
Paran N, Lustig S. Complement-bound human antibodies to vaccinia virus B5 antigen protect mice from virus challenge. Expert Rev Vaccines. 2010;9(3):255-9doi: 10.1586/erv.10.5.
Paran, N., & Lustig, S. (2010). Complement-bound human antibodies to vaccinia virus B5 antigen protect mice from virus challenge. Expert review of vaccines, 9(3), 255-9. https://doi.org/10.1586/erv.10.5
Paran, Nir, and Lustig, Shlomo. "Complement-bound human antibodies to vaccinia virus B5 antigen protect mice from virus challenge." Expert review of vaccines vol. 9,3 (2010): 255-9. doi: https://doi.org/10.1586/erv.10.5
Paran N, Lustig S. Complement-bound human antibodies to vaccinia virus B5 antigen protect mice from virus challenge. Expert Rev Vaccines. 2010 Mar;9(3):255-9. doi: 10.1586/erv.10.5. PMID: 20218853.
Copy Download .nbib Format: NLM
Immunity to smallpox and vaccinia: the future of smallpox vaccines.

Expert review of clinical immunology

Lane JM.
PMID: 20476903
Expert Rev Clin Immunol. 2006 May;2(3):325-7. doi: 10.1586/1744666X.2.3.325.

No abstract available.

Cite
Lane JM. Immunity to smallpox and vaccinia: the future of smallpox vaccines. Expert Rev Clin Immunol. 2006;2(3):325-7doi: 10.1586/1744666X.2.3.325.
Lane, J. M. (2006). Immunity to smallpox and vaccinia: the future of smallpox vaccines. Expert review of clinical immunology, 2(3), 325-7. https://doi.org/10.1586/1744666X.2.3.325
Lane, J Michael. "Immunity to smallpox and vaccinia: the future of smallpox vaccines." Expert review of clinical immunology vol. 2,3 (2006): 325-7. doi: https://doi.org/10.1586/1744666X.2.3.325
Lane JM. Immunity to smallpox and vaccinia: the future of smallpox vaccines. Expert Rev Clin Immunol. 2006 May;2(3):325-7. doi: 10.1586/1744666X.2.3.325. PMID: 20476903.
Copy Download .nbib Format: NLM
Emergence and reemergence of vaccinia-like viruses: global scenario and perspectives.

Indian journal of virology : an official organ of Indian Virological Society

Singh RK, Balamurugan V, Bhanuprakash V, Venkatesan G, Hosamani M.
PMID: 23729995
Indian J Virol. 2012 Jun;23(1):1-11. doi: 10.1007/s13337-012-0068-1. Epub 2012 Apr 04.

Among the members of the genus Orthopoxvirus (OPXV), vaccinia virus (VACV), the type species of the genus is a double-stranded DNA virus, belongs to the subfamily Chordopoxvirinae of the family Poxviridae. The causative agents of smallpox, VACV and Variola...

Cite
Singh RK, Balamurugan V, Bhanuprakash V, et al. Emergence and reemergence of vaccinia-like viruses: global scenario and perspectives. Indian J Virol. 2012;23(1):1-11doi: 10.1007/s13337-012-0068-1.
Singh, R. K., Balamurugan, V., Bhanuprakash, V., Venkatesan, G., & Hosamani, M. (2012). Emergence and reemergence of vaccinia-like viruses: global scenario and perspectives. Indian journal of virology : an official organ of Indian Virological Society, 23(1), 1-11. https://doi.org/10.1007/s13337-012-0068-1
Singh, R K, et al. "Emergence and reemergence of vaccinia-like viruses: global scenario and perspectives." Indian journal of virology : an official organ of Indian Virological Society vol. 23,1 (2012): 1-11. doi: https://doi.org/10.1007/s13337-012-0068-1
Singh RK, Balamurugan V, Bhanuprakash V, Venkatesan G, Hosamani M. Emergence and reemergence of vaccinia-like viruses: global scenario and perspectives. Indian J Virol. 2012 Jun;23(1):1-11. doi: 10.1007/s13337-012-0068-1. Epub 2012 Apr 04. PMID: 23729995; PMCID: PMC3550805.
Copy Download .nbib Format: NLM
[Not Available].

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz

Meyer C, Rasch G, Keller-Stanislawski B, Schnitzler N.
PMID: 24676981
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2002 Apr;45(4):364-70. doi: 10.1007/s00103-002-0391-6.

The decrease in infectious diseases preventable by immunisation and the absence of complications caused by these diseases leads to an increased awareness of vaccine-associated adverse events. The analysis of a survey of the vaccine injury compensation data from the...

Cite
Meyer C, Rasch G, Keller-Stanislawski B, et al. Anerkannte Impfschäden in der Bundesrepublik Deutschland 1990-1999. [Not Available]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2002;45(4):364-70doi: 10.1007/s00103-002-0391-6.
Meyer, C., Rasch, G., Keller-Stanislawski, B., & Schnitzler, N. (2002). Anerkannte Impfschäden in der Bundesrepublik Deutschland 1990-1999. [Not Available]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 45(4), 364-70. https://doi.org/10.1007/s00103-002-0391-6
Meyer, C, et al. "Anerkannte Impfschäden in der Bundesrepublik Deutschland 1990-1999." [Not Available]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz vol. 45,4 (2002): 364-70. doi: https://doi.org/10.1007/s00103-002-0391-6
Meyer C, Rasch G, Keller-Stanislawski B, Schnitzler N. Anerkannte Impfschäden in der Bundesrepublik Deutschland 1990-1999. [Not Available]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2002 Apr;45(4):364-70. doi: 10.1007/s00103-002-0391-6. German. PMID: 24676981.
Copy Download .nbib Format: NLM
A Critical Analysis of the Scientific and Commercial Rationales for the .

mSphere

Koblentz GD.
PMID: 29569633
mSphere. 2018 Mar 07;3(2). doi: 10.1128/mSphere.00040-18. eCollection 2018.

This article evaluates the scientific and commercial rationales for the synthesis of horsepox virus. I find that the claimed benefits of using horsepox virus as a smallpox vaccine rest on a weak scientific foundation and an even weaker business...

Cite
Koblentz GD. A Critical Analysis of the Scientific and Commercial Rationales for the . mSphere. 2018;3(2)doi: 10.1128/mSphere.00040-18.
Koblentz, G. D. (2018). A Critical Analysis of the Scientific and Commercial Rationales for the . mSphere, 3(2), . https://doi.org/10.1128/mSphere.00040-18
Koblentz, Gregory D. "A Critical Analysis of the Scientific and Commercial Rationales for the ." mSphere vol. 3,2 (2018). doi: https://doi.org/10.1128/mSphere.00040-18
Koblentz GD. A Critical Analysis of the Scientific and Commercial Rationales for the . mSphere. 2018 Mar 07;3(2). doi: 10.1128/mSphere.00040-18. eCollection 2018. PMID: 29569633; PMCID: PMC5853483.
Copy Download .nbib Format: NLM
Correction: A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis.

PloS one

Greenberg RN, Hurley MY, Dinh DV, Mraz S, Vera JG, von Bredow D, von Krempelhuber A, Roesch S, Virgin G, Arndtz-Wiedemann N, Meyer TP, Schmidt D, Nichols R, Young P, Chaplin P.
PMID: 26554703
PLoS One. 2015 Nov 10;10(11):e0142802. doi: 10.1371/journal.pone.0142802. eCollection 2015.

No abstract available.

Cite
Greenberg RN, Hurley MY, Dinh DV, et al. Correction: A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis. PLoS One. 2015;10(11):e0142802doi: 10.1371/journal.pone.0142802.
Greenberg, R. N., Hurley, M. Y., Dinh, D. V., Mraz, S., Vera, J. G., von Bredow, D., von Krempelhuber, A., Roesch, S., Virgin, G., Arndtz-Wiedemann, N., Meyer, T. P., Schmidt, D., Nichols, R., Young, P., & Chaplin, P. (2015). Correction: A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis. PloS one, 10(11), e0142802. https://doi.org/10.1371/journal.pone.0142802
Greenberg, Richard N, et al. "Correction: A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis." PloS one vol. 10,11 (2015): e0142802. doi: https://doi.org/10.1371/journal.pone.0142802
Greenberg RN, Hurley MY, Dinh DV, Mraz S, Vera JG, von Bredow D, von Krempelhuber A, Roesch S, Virgin G, Arndtz-Wiedemann N, Meyer TP, Schmidt D, Nichols R, Young P, Chaplin P. Correction: A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis. PLoS One. 2015 Nov 10;10(11):e0142802. doi: 10.1371/journal.pone.0142802. eCollection 2015. PMID: 26554703; PMCID: PMC4640813.
Copy Download .nbib Format: NLM
Vaccine humanity.

Journal of the American Pharmacists Association : JAPhA

Grabenstein JD.
PMID: 34903474
J Am Pharm Assoc (2003). 2021 Nov 19; doi: 10.1016/j.japh.2021.11.018. Epub 2021 Nov 19.

Vaccines to help prevent COVID-19 disease have evoked myriad human emotions. Attitudes of the public toward vaccination can be grouped into hundreds of categories. Pharmacists need to recognize the many elements of what may be termed "vaccine humanity," a...

Cite
Grabenstein JD. Vaccine humanity. J Am Pharm Assoc (2003). 2021;doi: 10.1016/j.japh.2021.11.018.
Grabenstein, J. D. (2021). Vaccine humanity. Journal of the American Pharmacists Association : JAPhA, . https://doi.org/10.1016/j.japh.2021.11.018
Grabenstein, John D. "Vaccine humanity." Journal of the American Pharmacists Association : JAPhA vol. (2021). doi: https://doi.org/10.1016/j.japh.2021.11.018
Grabenstein JD. Vaccine humanity. J Am Pharm Assoc (2003). 2021 Nov 19; doi: 10.1016/j.japh.2021.11.018. Epub 2021 Nov 19. PMID: 34903474.
Copy Download .nbib Format: NLM
Searching for the origin of the smallpox vaccine: Edward Jenner and his little-known horsepox hypothesis.

Vaccine

Esparza J, Damaso CR.
PMID: 34794823
Vaccine. 2021 Nov 15; doi: 10.1016/j.vaccine.2021.11.007. Epub 2021 Nov 15.

No abstract available.

Cite
Esparza J, Damaso CR. Searching for the origin of the smallpox vaccine: Edward Jenner and his little-known horsepox hypothesis. Vaccine. 2021;doi: 10.1016/j.vaccine.2021.11.007.
Esparza, J., & Damaso, C. R. (2021). Searching for the origin of the smallpox vaccine: Edward Jenner and his little-known horsepox hypothesis. Vaccine, . https://doi.org/10.1016/j.vaccine.2021.11.007
Esparza, José, and Damaso, Clarissa R. "Searching for the origin of the smallpox vaccine: Edward Jenner and his little-known horsepox hypothesis." Vaccine vol. (2021). doi: https://doi.org/10.1016/j.vaccine.2021.11.007
Esparza J, Damaso CR. Searching for the origin of the smallpox vaccine: Edward Jenner and his little-known horsepox hypothesis. Vaccine. 2021 Nov 15; doi: 10.1016/j.vaccine.2021.11.007. Epub 2021 Nov 15. PMID: 34794823.
Copy Download .nbib Format: NLM
Vaccine humanity.

Journal of the American Pharmacists Association : JAPhA

Grabenstein JD.
PMID: 34903474
J Am Pharm Assoc (2003). 2022 Jan-Feb;62(1):286-287. doi: 10.1016/j.japh.2021.11.018. Epub 2021 Nov 19.

Vaccines to help prevent COVID-19 disease have evoked myriad human emotions. Attitudes of the public toward vaccination can be grouped into hundreds of categories. Pharmacists need to recognize the many elements of what may be termed "vaccine humanity," a...

Cite
Grabenstein JD. Vaccine humanity. J Am Pharm Assoc (2003). 2021;62(1):286-287doi: 10.1016/j.japh.2021.11.018.
Grabenstein, J. D. (2022). Vaccine humanity. Journal of the American Pharmacists Association : JAPhA, 62(1), 286-287. https://doi.org/10.1016/j.japh.2021.11.018
Grabenstein, John D. "Vaccine humanity." Journal of the American Pharmacists Association : JAPhA vol. 62,1 (2022): 286-287. doi: https://doi.org/10.1016/j.japh.2021.11.018
Grabenstein JD. Vaccine humanity. J Am Pharm Assoc (2003). 2022 Jan-Feb;62(1):286-287. doi: 10.1016/j.japh.2021.11.018. Epub 2021 Nov 19. PMID: 34903474; PMCID: PMC8603871.
Copy Download .nbib Format: NLM
What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2?.

Vaccine: X

Hellerstein M.
PMID: 32875286
Vaccine X. 2020 Dec 11;6:100076. doi: 10.1016/j.jvacx.2020.100076. Epub 2020 Aug 28.

The first SARS-CoV-2 vaccine(s) will likely be licensed based on neutralizing antibodies in Phase 2 trials, but there are significant concerns about using antibody response in coronavirus infections as a sole metric of protective immunity. Antibody response is often...

Cite
Hellerstein M. What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2?. Vaccine X. 2020;6:100076doi: 10.1016/j.jvacx.2020.100076.
Hellerstein, M. (2020). What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2?. Vaccine: X, 6100076. https://doi.org/10.1016/j.jvacx.2020.100076
Hellerstein, Marc. "What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2?." Vaccine: X vol. 6 (2020): 100076. doi: https://doi.org/10.1016/j.jvacx.2020.100076
Hellerstein M. What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2?. Vaccine X. 2020 Dec 11;6:100076. doi: 10.1016/j.jvacx.2020.100076. Epub 2020 Aug 28. PMID: 32875286; PMCID: PMC7452821.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 64 entries